The Wolverine Stack
Also Known As: BPC TB stack, BPC+TB, BPC TB combo, TB BPC stack, BPC-157 Thymosin Beta-4 stack, BPC TB-500, TB500 BPC157 blend, Healing stack, Tissue repair stack, Recovery peptide stack, BPC 157 TB 500 combination, Soft tissue blend, healing blend, wolverine blend, BPC-157/TB-500, repair blend
The Wolverine Stack is a research-grade Peptide stack targeting Dual-pathway: BPC-157 via NO/VEGF/EGF studied in Peptide Stacks research. It is supplied strictly for in vitro laboratory research use only - not for human or animal consumption, and not FDA-approved.
Evidence Tier: Research Compound - No approved human use; sold for laboratory research only.
The common repair stack pairing BPC-157 with TB-500; preclinical, and banned in sport via TB-500.
At A Glance
| Category | Peptide Stacks |
|---|---|
| Compound Class | Peptide stack (BPC-157 + Thymosin Beta-4) |
| Molecular Target | Dual-pathway: BPC-157 via NO/VEGF/EGF; TB-500 via actin-G sequestration and VEGF upregulation |
| Molecular Weight | combination |
| Amino Acid Sequence | BPC-157 + Thymosin beta-4 fragment |
| CAS Number | n/a |
| Half-Life | ~30 minutes (BPC-157) / ~30 hours (TB-500) |
| WADA Status | prohibited |
| Evidence Tier | Research Compound |
Mechanism Of Action
It combines two actions: one peptide creates new blood flow networks to the injury, while the other peptide tells repair cells to physically crawl into the wound and start rebuilding tissue.
Studied For
- Soft-tissue repair research
- Combined healing and regeneration
- Tendon repair acceleration
- Ligament healing
- Muscle injury recovery
- Sports injury research
- Post-surgical healing
- Wound closure acceleration
- Joint repair
- Anti-inflammatory synergy
- Nerve regeneration with tissue repair
- Comprehensive tissue healing protocol
- GI healing with systemic repair
- Athletic recovery research
- Injury rehabilitation research
- tissue repair
- joint healing
- recovery
- muscle tear
- inflammation
- systemic healing
Reported Research Findings
No controlled human combination-trial evidence exists; both components are preclinical in this context.
Safety And Handling Notes
Inherits both components: limited human safety data and a doubled pro-angiogenic theoretical tumor caveat.
Both components are unapproved; TB-500 is WADA-prohibited and BPC-157 falls under WADA non-approved-substance rules. Research use only.
Regulatory Status
Not FDA-approved; TB-500 WADA-prohibited.
Full Reference Detail
Related Research Guides
Maintained By The Pep Nation Lab Research Team. See Our Editorial Standards And Research Methodology For How This Reference Is Sourced And Reviewed.
This Reference Is Provided For In Vitro Laboratory Research Use Only. Not For Human Consumption. See The Full Research Disclaimer.